GlucoGuard, a Division of American Diversified Holdings (ADHC), Has Completed an Investors Deck Focused on Funding Research Required for FDA Approval
Glucoguard Successfully Submits Revised Level 2 App Integration Through Dexcom's Developer Partner Program DEL MAR, CA / ACCESS Newswire / September 23, 2026 / American Diversified Holdings Corporation (OTCID:ADHC) announced today that GlucoGuard …
Glucoguard Successfully Submits Revised Level 2 App Integration Through Dexcom's Developer Partner Program
DEL MAR, CA / ACCESS Newswire / September 23, 2026 / American Diversified Holdings Corporation (OTCID:ADHC) announced today that GlucoGuard has completed an Investors Deck focused on raising research related Capital.
The Deck can be found at www.GlucoGuardSleep.com under the DECK tab; password "Admin123".
The company is currently in discussions with several institutional investors that have expressed strong interest in financing GlucuGuard's development.
The company anticipates aggressively moving forward once financing is secured. The previously announced plan for a spinoff is currently being incorporated into the financing negotiations. It should be noted that a reverse split will not be considered.
Additionally, Glucoguard completed an updated and revised Level 2 App integration through DEXCOM's Developer Program. The project development is in conjunction with UC Irvine's MADO program through the California Institute for Telecommunications and Information Technology (CALIT2a).
The Dexcom Developer Program is a partnership program that allows developers to access Dexcom API and integrate Dexcom CGM data into their own applications. Dexcom partners with the company to gain access to app credentials, sand box data, and development support. The Dexcom API allows partners to integrate DEXCOM CGM Data, such as glucose levels, into their applications.
It is expected that in mid-June, the next level of App integration development will be approved, resulting in a fully functional back-end to front-end completion where the app will run on a mobile device.
Developments Include:
- A functional front-end and back-end App capable of running on an emulator
- A trained predictive algorithm for detecting hypoglycemia episodes with 95% accuracy
- Secured Registered Developer access to the Dexcom API, enabling initial integration with continuous glucose monitoring (CGM) data
GlucoGuard is also developing a suite of AI features designed to predict negative blood glucose events and mitigate these events before the patient suffers catastrophic adverse effects. The ability to manage glucose in this manner is a groundbreaking advancement that will truly establish GlucoGuard as a revolutionary technology in the field of diabetes - a multibillion-dollar industry.

